EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, provides a trading update which reflects lower than expected revenue,
€3.2m contract for Venn Life Sciences with global pharmaceutical client
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Buying lottery tickets on the FTSE AIM can be very rewarding, but only for investors who have already properly diversified.
Launch of Broker Offer to raise a maximum of £500,000
Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
According to data from central Henan’s health commission, 88 million people may have been infected with the virus.
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to